Bolt Biotherapeutics to Participate in September Investor Conferences

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in September:

• Morgan Stanley 21st Annual Global Healthcare Conference Fireside chat on Tuesday, Sept. 12, at 3:35 p.m. EDT (12:35 p.m. PDT)

• H.C. Wainwright 25th Annual Global Investment Conference Management will be available for one-on-one meetings with investors on Wednesday, Sept. 13

A live webcast of the Morgan Stanley fireside chat will be available on the Events and Presentations page of Bolt’s website at www.boltbio.com. Archived replays will be available for 30 days following the event.

About Bolt Biotherapeutics, Inc. Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-1001, a HER2-targeting Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. BDC-1001 is currently in Phase 2 clinical development following the successful completion of a Phase 1 dose-escalation trial that demonstrated tolerability and early clinical efficacy. BDC-3042, an agonist antibody targeting Dectin-2, is expected to initiate a Phase 1 trial in the second half of 2023. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. Bolt Biotherapeutics is also developing multiple Boltbody™ ISACs in strategic collaborations with leading biopharmaceutical companies. For more information, please visit https://www.boltbio.com/For more information, please visit https://www.boltbio.com/

Investor Relations and Media Contacts:

Paige KellyStern Investor Relations, [e-mail]

David SchullRusso Partners, [e-mail]